Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001018912 | SCV001180207 | pathogenic | Hereditary cancer-predisposing syndrome | 2018-10-30 | criteria provided, single submitter | clinical testing | The p.K305* pathogenic mutation (also known as c.913A>T), located in coding exon 7 of the TP53 gene, results from an A to T substitution at nucleotide position 913. This changes the amino acid from a lysine to a stop codon within coding exon 7. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV003509646 | SCV004315207 | pathogenic | Li-Fraumeni syndrome | 2023-08-23 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Lys305*) in the TP53 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TP53 are known to be pathogenic (PMID: 20522432). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 823045). This variant has not been reported in the literature in individuals affected with TP53-related conditions. This variant is not present in population databases (gnomAD no frequency). |
Laboratory for Genotyping Development, |
RCV003160179 | SCV002758164 | pathogenic | Gastric cancer | 2021-07-01 | no assertion criteria provided | research |